Denninghoff Valeria, Allende Daniela, Paesani Fernando, Garcia Alejandro, Avagnina Alejandra, Perazzo Florencia, Abalo Eduardo, Crimi Gabriel, Elsner Boris
Pathology, Center for Medical Education and Clinical Investigation (CEMIC), Buenos Aires, Argentina.
Diagn Mol Pathol. 2008 Dec;17(4):214-9. doi: 10.1097/PDM.0b013e3181601777.
The prognosis of breast cancer patients depends on primary tumor resection and axillary lymph nodes examination. The purpose of this study was to analyze by molecular biology techniques the presence of mammaglobin A and B messenger RNA in breast sentinel lymph node (SLN) by reverse-transcription polymerase chain reaction (RT-PCR).
Sentinel lymph nodes from 50 patients with a diagnosis of breast cancer were prospectively studied between June 2004 and August 2006. Lymph nodes were all examined every 2 mm by intraoperative cytology. Hematoxylin-eosin (HE), immunohistochemistry (IHC) with cytokeratin (clone AE1-AE3, DAKO, dilution 1:100), and molecular biology techniques were used in all cases.
Deferred study with routine techniques showed subcapsular metastasis in 3/50 cases. Out of 50 cases, 5 were detected with IHC, and 2 of them were negative for HE. Multiplex RT-PCR allowed the detection of 18/50 positive SLN, which included the 5 above-mentioned cases. The other SLN studied (32/50) showed no metastases with the methods herein implemented.
The epidemiologic impact of incomplete SLN study has been observed, as the HE technique fails to identify all SLN with micrometastases. In our opinion, SLN should be studied with IHC and molecular biology techniques. The multiplex RT-PCR technique for A and B mammaglobin proves to be specific and sensitive. This study will serve to formulate hypotheses. Further research, including a larger population and a longer-term follow-up period, will be required to confirm these hypotheses. Should our findings be confirmed in the future, molecular biology determinations could modify patients' staging and treatment.
乳腺癌患者的预后取决于原发肿瘤切除及腋窝淋巴结检查。本研究的目的是通过逆转录聚合酶链反应(RT-PCR),运用分子生物学技术分析乳腺前哨淋巴结(SLN)中乳腺珠蛋白A和B信使核糖核酸的存在情况。
对2004年6月至2006年8月期间50例确诊为乳腺癌的患者的前哨淋巴结进行前瞻性研究。术中对淋巴结每隔2毫米进行细胞学检查。所有病例均采用苏木精-伊红(HE)染色、细胞角蛋白免疫组织化学(IHC)(克隆AE1-AE3,DAKO,稀释度1:100)及分子生物学技术。
常规技术延迟研究显示50例中有3例存在包膜下转移。50例中,免疫组织化学检测出5例,其中2例HE染色为阴性。多重RT-PCR检测出50例中有18例前哨淋巴结阳性,其中包括上述5例。采用本文所实施方法对其他前哨淋巴结(32/50)进行检测,未发现转移。
已观察到前哨淋巴结研究不完整的流行病学影响,因为HE技术无法识别所有存在微转移的前哨淋巴结。我们认为,前哨淋巴结应采用免疫组织化学和分子生物学技术进行研究。乳腺珠蛋白A和B的多重RT-PCR技术被证明具有特异性和敏感性。本研究将有助于提出假设。需要进一步的研究,包括更大规模的人群和更长时间的随访期,以证实这些假设。如果我们的发现未来得到证实,分子生物学检测可能会改变患者的分期和治疗。